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The effect of directly observed therapy (DOT) versus self-administered therapy (SAT) on 
antiretroviral (ART) adherence and virological outcomes in prison has never been assessed in a 
randomized, controlled trial. Prisoners were randomized to receive ART by DOT or SAT. The 
primary outcome was medication adherence [percent of ART doses measured by the medication 
event monitoring system (MEMS) and pill counts] at the end of 24 weeks. The changes in the 
plasma viral loads from baseline and proportion of participants virological suppressed (<400 
copies/mL) at the end of 24 weeks were assessed. Sixty-six percent (90/136) of eligible prisoners 
declined participation. Participants in the DOT arm (n = 20) had higher viral loads than 
participants in the SAT (n = 23) arm (p = 0.23). Participants, with complete data at 24 weeks, were 
analyzed as randomized. There were no significant differences in median ART adherence between 
the DOT (n = 16, 99% MEMS [IQR 93.9, 100], 97.1 % pill count [IQR 95.1, 99.3]) and SAT (n = 
21, 98.3 % MEMS [IQR 96.0, 100], 98.5 % pill count [95.8, 100]) arms (p = 0.82 MEMS, p = 
0.40 Pill Count) at 24 weeks. Participants in the DOT arm had a greater reduction in viral load of 
approximately −1 log 10 copies/mL [IQR −1.75, −0.05] compared to −0.05 [IQR −0.45, 0.51] in 
the SAT arm (p value = 0.02) at 24 weeks. The proportion of participants achieving virological 
suppression in the DOT vs SAT arms was not statistically different at 24 weeks (53 % vs 32 %, p 
= 0.21). These findings suggest that DOT ART programs in prison settings may not offer any 
additional benefit on adherence than SAT programs.
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Introduction
Suboptimal adherence to antiretroviral therapy (ART) can lead to continued viral 
replication, viral drug resistance, disease progression, and increased infectiousness [1–5]. 
However, achieving levels of adherence sufficient to maintain viral suppression is 
challenging for many patients. Directly observed therapy (DOT) has been proposed as an 
intervention to ensure “near perfect” adherence to ART [5, 6]. It has been widely adopted in 
prisons and other supervised settings where it is used for both HIV and non-HIV-related 
medications.
Despite the widespread use of DOT in prison, there are several factors that make DOT ART 
in prison challenging. First, prisoners often have to wait in long lines to receive their 
medications [7]. Second, the medications may be given at inconvenient times. Further, 
prisoners waiting in the DOT line may experience lack of confidentiality and feel 
stigmatized [8–10]. Finally, prisoners often do not trust the correctional officers and nurses 
staffing the DOT line to administer the correct antiretroviral medications [11].
Despite these factors, several studies of HIV infected prisoners have reported high levels of 
adherence or virological suppression with ART delivered by DOT but have had major 
methodological limitations [12, 13]. One study found greater viral suppression among 
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prisoners in Florida receiving ART via DOT compared to non-incarcerated HIV clinical trial 
participants who self-administered ART (SAT) [14]. The non-randomized design of the 
Florida study precluded the ability to distinguish the effects of the use of DOT from other 
confounding factors [14]. A trial involving four state prison systems, found that prisoners 
who received ART by DOT reported 94 % adherence with 85 % achieving virologic 
suppression [15]. However, this trial lacked an SAT comparison group. In contrast, in two 
observational studies, there were no differences in ART adherence between prisoners who 
received ART either by DOT or SAT [12, 16].
Because DOT is a common, expensive, labor-intensive policy adopted for ART 
administration among many prison systems, studies with more rigorous designs are 
warranted to determine the efficacy of DOT in enhancing ART adherence and virological 
outcomes in prisons [17, 18].
To compare the effect of DOT versus SAT on medication adherence in a correctional 
setting, we conducted a pilot of a randomized controlled trial of DOT versus SAT delivery 
of ART in a state prison system. Our primary objective was to determine the efficacy of 
DOT versus SAT in enhancing adherence to ART at 24 weeks. Our secondary objectives 
were to compare the adherence of both arms at 48 weeks, and to compare the changes in 
plasma HIV RNA levels and CD4+ lymphocyte cell counts between both arms at 24 and 48 
weeks. Because our non-randomized pilot research had not demonstrated the superiority of 
DOT over SAT on ART adherence [12], we hypothesized that there would be no difference 
in adherence between prisoners receiving ART by DOT or self-administration.
Methods
Study site and Participants
The study was conducted in the North Carolina State prison system from 8/5/2003–
2/16/2005. At the time of the study, 640 HIV-infected men and women were incarcerated at 
74 correctional facilities across the state [19, 20]. Sixty percent of the total HIV-infected 
prison population were housed in 11 of the largest 74 facilities [19]. We limited our study to 
these 11 facilities because of their capacity to directly observe antiretrovirals every day of 
the week.
Men and women prisoners were consecutively recruited from three prison-based HIV clinics 
where approximately 85 % of the total HIV-infected population received outpatient HIV 
care. Prisoners were eligible for the study if they were: documented to have HIV infection; 
currently receiving or initiating ART; housed at one of the 11 participating facilities with no 
planned inter-prison transfers; had a Karnofsky score ≥70, indicating capability for self-care; 
were at least 18 years of age; expected to be incarcerated ≥6 months; and had a CD4+ T-
lymphocyte count and a plasma HIV RNA level within 60 days of study entry. Potential 
participants were excluded if they had active mental illnesses or conditions that would 
preclude informed consent or completion of study requirements.
All participants provided informed consent before enrollment. Consent was obtained in a 
private room by research personnel. Participants were informed that joining the study would 
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not affect their health care, terms of confinement, or release from prison. The study was 
approved by the University of North Carolina Biomedical Institutional Review Board, North 
Carolina Department of Public Safety's (NCDPS) Human Subjects Review Committee, and 
the US Department of Health and Human Services Office of Human Research Programs 
(OHRP). Participants received no incentives, financial or otherwise (per NCDPS Human 
Subjects Review policy), for study participation.
Standard of Care and Intervention Design
Standard of Care—At the time of the trial, it was standard of care per prison policy for 
prison staff (nurses, nursing assistants or correctional officers) to administer all doses of 
protease inhibitors by DOT to enhance adherence and reduce downstream costs due to non-
adherence [12, 21]. Non-nucleoside and nucleoside reverse-transcriptase inhibitors could 
either be directly observed or self-administered. After each DOT event, prison staff would 
record whether or not the inmate took the ART. Per North Carolina prisons' protocol, if 
prisoners missed more than 3 days of directly observed antiretrovirals, the prison staff were 
to notify the prison physicians, nurses or HIV clinicians. Prisoners participating in the self-
administered medication program were directed to turn in any remaining medications at 
each monthly refill.
Intervention Design and Randomization—Participants were randomly assigned in a 
1:1 ratio to DOT or SAT using permuted block randomization. The randomization schedule 
was maintained by personnel at a central study site away from study personnel.
DOT Arm—In the DOT arm, prison staff observed each inmate ingest all of their 
antiretroviral medications per prison DOT protocol.
SAT Arm—In the SAT arm, participants received monthly allotments of all of their 
antiretroviral medications, including their protease inhibitors, from prison staff and were 
required to sign for each antiretroviral medication bottle.
Optional Adherence Counseling—After week 24, all participants had the option of 
receiving two standardized Motivational Interviewing sessions by trained health educators 
focused on helping them identify strategies to address adherence to ART.
Study Outcomes
Primary Outcome
The primary outcome was ART Adherence at 24 weeks. This was determined by the percent 
of prescribed ART doses taken during 20–24 weeks as measured by Medication Event 
Monitoring System pill caps (MEMS; Aardex, Switzerland) and Pill Count in both arms.
Secondary Outcomes
We assessed the percent of prescribed ART doses taken at 48 weeks (44–48 week period) as 
well as the odds (DOT vs. SAT) of achieving greater than or equal to 95 % adherence over 
the entire 24 and 48 week time period. We assessed for the change in plasma HIV-1 RNA 
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levels (log10 copies/mL) and CD4+ T-lymphocyte counts from baseline values to 24 weeks 
and baseline values to 48 weeks. We also determined the plasma HIV-1 RNA levels (log10 
copies/mL) and proportion of participants virologically suppressed (plasma HIV RNA level 
≤400 copies/mL) at the end of weeks 24 and 48.
Data Collection
Participants' demographic, clinical, and laboratory data were abstracted from prison 
administrative and medical records using standardized chart abstraction forms. Participants 
received laboratory assessments (plasma HIV RNA levels, CD4+ T-lymphocyte counts) at 
approximately 0, 12, 24, 36, and 48 weeks. Participants' MEMS caps and pill bottles were 
collected at the end of each 4-week period. The MEMS caps were sent to UNC CH and 
downloaded to a designated research computer. The pill bottles were sent to the main prison 
pharmacy to determine the remaining pills in each bottle using an automatic pill counter.
Measurement of Adherence
We assessed antiretroviral adherence using MEMS (Aardex, Switzerland) and Pill Count. 
Adherence was measured as the number of MEMS events (pill bottle openings) in one4 
week time period divided by the number of prescribed doses, multiplied by 100 [22]. Prison 
pharmacy staff placed a MEMS device on one pill bottle from each participant's 
antiretroviral regimen at monthly refills. The MEMS device was placed on the bottle of the 
antiretroviral medication with the most complexity. We used the following to rank the 
complexity of each antiretroviral medication: Rank = daily pill frequency + (total number of 
pills taken daily/2) [5, 23–26]. We used the same complex antiretroviral per regimen (as 
above) to determine the Pill count. The Pill count was determined as the (number of pills 
dispensed-number of pills left)/number of pills dispensed) multiplied by 100. See the 
Appendix—Supplementary materials for examples.
Statistical Analyses
All statistical analyses were conducted using SAS version 9.3 and R version 2.15. 
Descriptive statistics were used to summarize baseline demographical and clinical 
characteristics. We compared the adherence, immunological and virological outcomes 
between the two study arms. All participants with complete data were included in the 24 and 
48 week analyses, respectively. All participants were analyzed as randomized.
Wilcoxon rank sum tests were used to compare adherence levels between the DOT and the 
SAT arms during both the 20–24 and the 44–48 week time periods. Logistic mixed models 
were employed to estimate the odds ratios (OR) for achieving greater than 95 % adherence 
between the two arms. These models included time since randomization as a linear 
continuous covariate and an interaction term between time and study arm. Random effects 
included participant specific time slopes and intercepts. Because of the attrition of 
participants at 24 and 48 weeks, we conducted a sensitivity analysis to determine the extent 
that loss of these participants may have affected the tests to determine differences in 
adherence between the two arms (see Appendix—Supplementary materials).
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To compare the CD4+ T lymphocyte counts and HIV RNA levels (log10 copies/mL) 
between the DOT and SAT arms at the end of weeks 24 and 48, respectively, we used the 
Wilcoxon rank sum tests. To compare HIV RNA levels at the end of 24 and 48 weeks 
between the two arms (adjusting for baseline log10 viral loads), we used the t test. To 
compare the proportion of participants virally suppressed at ≤400 copies/mL between the 
two arms at the end of weeks 24 and 48, we used the Fisher's exact test.
Linear mixed models were fit to assess the effect of study arm on the changes in CD4+ T 
lymphocyte counts and HIV RNA levels (log10 viral load) from baseline to weeks 24 and 
48. Logistic mixed effects models were used to assess the effect of study arm on the binary 
outcome of interest (virological suppression defined as <400 copies/mL). The models 
included as fixed effects time since randomization, study arm, and interaction between time 
and study arm. Random effects included participant specific time slopes and intercepts.
Results
Participation and Sample Baseline Characteristics (Table 1)
Eleven of the 20 participants (55 %) in the DOT arm and 8 of the 23 (35 %) participants in 
the SAT arm were ART na(x000EF)ve prior to randomization (p = 0.23). Participants in the 
DOT arm had significantly higher HIV-1 RNA levels (log10 copies/mL) at baseline study 
entry compared to their SAT counterparts (p < 0.05). A higher proportion of participants 
randomized to the SAT arm were virologically suppressed as compared to the DOT arm (p < 
0.05).
The disposition of patients screened and enrolled is shown in Fig. 1. During the initial phase 
of recruitment (8/05/03–11/26/03), 36 % (13/36) of eligible prisoners refused. The most 
commonly reported reason was unwillingness to change their mode of antiretroviral 
administration. Thus, eligible prisoners (both those who, at the time of study recruitment, 
were taking their ART medication as DOT and those who were taking it as SAT) preferred 
to keep their current mode of antiretroviral administration. Because of our experiences of 
eligible prisoners declining participation in the RCT due to ART mode preference, we 
offered prisoners an additional study option during the second phase of study recruitment 
(12/05/03–9/03/04). Prisoners were offered the option to participate in a parallel 
observational cohort study of ART adherence. In this observational study, participants were 
allowed to continue their current mode of ART. Findings from the observational cohort 
study are described elsewhere (unpublished data). During this second phase of recruitment, 
83 % (83/100) of participants agreed to participate in either study. Twenty elected to 
participate in the RCT and 60 elected to participate in the observational cohort study. Thus, 
the RCT refusal rate during the second phase was 77 % of eligible (77/100) prisoners with 
77 % of those refusing the RCT (60/77) electing to participate in the observational cohort 
study. Overall, 66 % (90/136) of eligible participants, declined participation in the RCT. 
Approximately half (n = 22) of the original participants remained in the trial at week 48. 
This was largely due to the slow pace of recruitment leaving insufficient time for those 
recruited later in the study to reach 48 weeks. Nine of the DOT participants and 14 of the 
SAT participants opted to receive adherence counseling approximately 25 and 26 weeks 
after randomization. There were no deaths in either arm during the 48 week study period.
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There were no clinically or statistically significant differences in MEMS or Pill Count 
adherence between the DOT and SAT arms at 24 or 48 weeks (Table 2). At 24 weeks, the 
median MEMS adherence was 99.0 % [IQR 93.9, 100] in the DOT arm and 98.3 % [IQR 
96.0, 100] in the SAT arm (p = 0.82). The median pill count adherence at 24 weeks was 97.1 
% [IQR 95.1, 99.3] in the DOT arm and 98.5 % [IQR 95.8–100] in the SAT arm (p = 0.40). 
Similarly, there were no difference between study arms in MEMS or pill count adherence at 
48 weeks (p = 0.79 and p = 0.84 respectively). There was no statistically significant 
difference in the odds of achieving greater than 95 % adherence in the DOT versus SAT arm 
respectively as measured by MEMS or pill count (ORmems 0.77, p = 0.77; ORpill count 1.28, 
p = 0.75).
We conducted a sensitivity analysis for the MEMS and Pill count adherence outcomes to 
determine if the loss of trial participants resulted in a statistically significant difference in 
adherence between the DOT and SAT arms. We found no statistically significant differences 
in adherence between the two arms at 24 or 48 weeks (see Appendix—Supplementary 
materials).
Virological and Immunological Outcomes
There was a significantly greater decrease in HIV-1 RNA levels (log10 copies/mL) from 
baseline in the DOT arm as compared to the SAT arm at both 24 (p = 0.02) and 48 weeks (p 
= 0.01). Because the baseline viral load was higher in the DOT arm, we adjusted for baseline 
differences between the two arms. In the adjusted analysis, there was no difference in the 
final HIV-1 RNA levels (log10 copies/mL) at the end of 24 or 48 weeks (p 0.27 vs. p 0.16).
Similarly, the proportion of participants achieving viral suppression did not differ 
significantly between the two study arms at week 24 or 48 (p 0.21 vs. 0.48, see Table 3). In 
the adjusted analysis (for baseline viral load), there remained no differences in the 
proportion of participants achieving viral suppression at week 24 or 48 (data not shown). 
Further, using a linear mixed model (adjusting for baseline viral load) we found no 
differences in plasma HIV RNA levels (log10 copies/mL) between the two arms (p = 0.93). 
Using a logistic mixed effects model, we again found no significant differences between the 
two arms in achieving viral suppression (p = 0.47).
There was also no significant increase or decrease in CD4+ T lymphocyte counts (from 
baseline) between the two arms at the end of weeks 24 (p = 0.69) or 48 (p = 0.98). In 
multivariate analysis (linear mixed effect model) adjusting for baseline viral load, we again 
found no significant differences between the two arms with respect to change in CD4+ T 
lymphocyte from baseline to week 48 (p = 0.21).
Discussion
In this randomized controlled trial in a prison of DOT versus SAT, we found no difference 
in antiretroviral adherence or CD4+ T-lymphocyte counts between prisoners receiving DOT 
versus SAT. Median antiretroviral adherence in both arms was high at greater than 95 % 
throughout the study. At the end of 24 weeks, DOT participants had a significantly greater 
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viral load reduction of −1 log10 copies/mL from baseline compared to a 0 reduction in the 
SAT participants. However, there were no differences between the two arms in HIV RNA 
levels or proportion virologically suppressed at the end of 24 or 48 weeks.
Several possibilities may explain the greater virological reduction without differences in 
adherence in the DOT arm compared to the SAT arm. First, the differences in the decrease 
in viral load from baseline between the two arms could have been attributable to baseline 
differences and not to randomization. Alternatively, DOT could be superior to SAT in 
achieving virological benefits without improving adherence, as seen by Altice et al. [27]. 
For example, participants receiving DOT may receive closer monitoring by clinicians 
resulting in modifications to regimens as needed to improve their efficacy [27]. Further, our 
major adherence outcomes measured adherence at the end of weeks 24 and 48. However, 
differences in the earlier weeks of adherence could have affected viral load. Further, we did 
not compare the patterns of adherence which may have differed between the two arms and 
have been shown to affect virological outcomes [28].
We were not able to demonstrate any overall advantage of DOT in terms of adherence, 
immunological outcomes, or achievement of virological suppression. Our results were 
consistent with findings from recent systematic reviews and meta-analyses of DOT versus 
SAT ART when restricted to randomized controlled trials [29]. However, our results do not 
definitively demonstrate that DOT has no role in supporting ART adherence in prisons. 
DOT interventions may be particularly effective in prisoners and non-prisoners with poor 
adherence [27, 29, 30].
Our results contrast with findings of non-randomized prison trials of DOT ART, which 
show that DOT produces greater virological suppression than SAT [13, 14]. While DOT 
may not be superior to SAT, previous prison studies of DOT were nonrandomized and their 
positive results may be due to confounding. Also, the components of the DOT intervention 
in our study may be substantially different than the DOT components in other prison studies. 
Third, even if the intended DOT intervention components were similar, the non-randomized 
studies may not have been designed to maintain the same degree of fidelity to the DOT 
protocol [29].
This study has several limitations. First, due to its small sample size, it lacked power to 
detect small differences in adherence and to detect differences in later secondary outcomes 
at 48-week follow-up. Given the high levels of adherence in both arms, it is doubtful that an 
increase in sample size would have yielded clinically significant differences of 10 % 
adherence [31, 32]. Refusals during participant recruitment may have introduced selection 
bias. However, it is reassuring that prisoners felt comfortable refusing study participation 
given the ethical imperative to avoid coercive prison research participation [33, 34]. Finally, 
DOT and SAT may differ in their effects on other important health outcomes, like prisoner 
satisfaction, quality of life, hospitalizations or costs, which was beyond the scope of this 
pilot trial.
We were surprised by the high refusal rate in this study given our previous research showing 
a general dislike of DOT. We believed that prisoners on DOT ART would agree to 
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participate in a study where they had a chance to change their mode of ART administration. 
However at the time of the study, prisoners were increasingly being prescribed non-
nucleoside reverse transcriptase inhibitors (NNRTI). These medications do not require direct 
observation per prison policy. Therefore, we had fewer eligible participants on DOT than 
expected, and who were willing to risk an ART administration change. In addition, some 
prisoners on DOT ART preferred to have their antiretrovirals directly observed by prison 
staff.
Despite these limitations, our study does not support DOT as more efficacious at enhancing 
adherence to complex ART medications or at achieving virological suppression than SAT 
among HIV infected prisoners. HIV-infected prisoners achieved near-perfect adherence 
under both sets of conditions, suggesting widespread use of DOT ART among incarcerated 
populations should be questioned [35]. These findings add to a much needed evidence-base 
for ART adherence interventions for HIV-infected inmates. The greater challenge is to 
determine the best strategies to help HIV-infected prisoners maintain their high levels of 
adherence and virological suppression after release into their communities [36, 37].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. The disposition of study participants
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Table 1
Baseline characteristics of the 43 randomized controlled trial prison participants 
administered antiretrovirals by direct observation (DOT) versus self-administration 
(SAT)
Characteristic DOT N = 20 (%) SAT N = 23 (%) p
Age, median years [IQR] 38 [34, 38] 39 [36, 39] 0.39
Male sex 17 (85 %) 20 (87 %) 1.00
Race/Ethnicity 0.26
 African-American 13 (65 %) 18 (78 %)
 White 2 (10 %) 1 (4 %)
 Native American 3 (15 %) 0 (0 %)
 Hispanic/latino 0 (0 %) 1 (4 %)
 Multiracial or other 2 (10 %) 3 (13 %)
Highest educational levela 0.18
 8th grade or less 1 (5 %) 0 (0 %)
 Some High School 6 (30 %) 12 (52 %)
 High School Graduate/GED 4 (20 %) 5 (22 %)
 Some College 2 (10 %) 5 (22 %)
 College Graduate 5 (25 %) 1 (4 %)
 More than 4 year College Degree 1 (5 %) 0 (0 %)
Baseline laboratory values
 Plasma HIV RNA level <400 copies/mL 2 (10 %) 12 (55 %) 0.004
 HIV-1 RNA level, median log10 copies/mL [IQR] 3.35 [2.94, 4.47] 2.60 [2.09, 3.20] 0.01
 CD4+ T Lymphocyte count, median cells/μL [IQR] 461 [249, 911] 465 [312, 655] 0.96
Antiretroviral naive before study entry 11 (55 %) 8 (35 %) 0.23
 Antiretroviral regimens received at study entry 0.47
 PI + NRTIs 5 (25 %) 7 (30 %)
 Ritonavir-boosted PI + NRTIs 6 (30 %) 4 (17 %)
 NNRTI + NRTIs 7 (35 %) 9 (39 %)
 NRTIs only 1 (5 %) 1 (4 %)
 PI + NNRTI + NRTIs 1 (5 %) 0 (0 %)
 Ritonavir-boosted PI + PI + NRTIs 0 (0 %) 2 (9 %)
HIV risk factor or mode of transmissionb 0.82
 Homosexual contact (MSM) 1 (5 %) 2 (9 %)
 Heterosexual contact 13 (65 %) 16 (70 %)
 Injection drug use 7 (35 %) 8 (35 %)
 Other 0 (0 %) 0 (0 %)
Illegal substance abuse historya,c 16 (80 %) 20 (87 %) 0.69
Depressiond 4 (20 %) 8 (35 %) 0.32
a
Missing data for education level (n = 1, DOT arm) and substance abuse history (n = 1 DOT, arm, n = 2, SAT arm)
b
Participants could be in more than one category if they listed multiple risk factors






















White et al. Page 14
c
Participants were classified as having an illegal substance abuse history if they had ever used amphetamines, crack/cocaine, ecstasy, heroin or 
marijuana
d
At study entry, participants were asked two emotional well-being items from the short-form health survey (SF-36). The questions were how much 
of the time during the past 4 weeks have you felt 1) “down in the dumps that nothing could cheer you up” or 2) “downhearted and depressed?” 
Participants were classified as depressed if they answered “all” or “most of the time” to either of the two items
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